Clinical Trial Results:
A 16-week treatment, multicenter, randomized, double blind, placebo-controlled, parallel-group study to assess the effect of omalizumab on the expression of FcεRI receptors of blood basophils and dendritic cells in patients with severe persistent non-atopic asthma, uncontrolled despite optimal therapy.
Summary
|
|
EudraCT number |
2009-010937-38 |
Trial protocol |
FR |
Global completion date |
23 Feb 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Apr 2016
|
First version publication date |
21 Apr 2016
|
Other versions |
|
Summary report(s) |
CIGE025AFR05_CT_gov_results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.